Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001437749-25-026967
Filing Date
2025-08-14
Accepted
2025-08-14 16:32:05
Documents
61
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q rvph20250630_10q.htm   iXBRL 10-Q 1235903
2 EXHIBIT 31.1 ex_847049.htm EX-31.1 11120
3 EXHIBIT 31.2 ex_847050.htm EX-31.2 11165
4 EXHIBIT 32.1 ex_847051.htm EX-32.1 7855
10 efficacy01.jpg GRAPHIC 43224
11 safety01.jpg GRAPHIC 46232
12 summsafety01.jpg GRAPHIC 57479
  Complete submission text file 0001437749-25-026967.txt   6087731

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA rvph-20250630.xsd EX-101.SCH 52155
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE rvph-20250630_def.xml EX-101.DEF 326636
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE rvph-20250630_lab.xml EX-101.LAB 270725
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rvph-20250630_pre.xml EX-101.PRE 352656
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE rvph-20250630_cal.xml EX-101.CAL 24439
64 EXTRACTED XBRL INSTANCE DOCUMENT rvph20250630_10q_htm.xml XML 1010853
Mailing Address 10080 N WOLFE ROAD SUITE SW3-200 CUPERTINO CA 95014
Business Address 10080 N WOLFE ROAD SUITE SW3-200 CUPERTINO CA 95014 4085018881
REVIVA PHARMACEUTICALS HOLDINGS, INC. (Filer) CIK: 0001742927 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38634 | Film No.: 251220015
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)